Pacira BioSciences Forecasts 2024 Revenue Of $680M-$705M Versus Consensus Of $716.62M, With Adjusted Gross Margin Of 74%-76%
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences projects its 2024 revenue to be between $680M-$705M, which is below the consensus estimate of $716.62M. The company also anticipates an adjusted gross margin of 74%-76%.
February 29, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences forecasts its 2024 revenue to fall below consensus estimates, with an expected range of $680M-$705M and an adjusted gross margin of 74%-76%.
The projected revenue for 2024 being below consensus estimates could lead to negative investor sentiment in the short term, potentially impacting the stock price negatively. However, the solid adjusted gross margin projection may mitigate some concerns.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100